Login Register Cart 0
Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Pharmacogenetics for Improving Efficacy and Safety in Drug Development and for Reducing Costs in Alzheimer’s Disease

Author(s): Ramón Cacabelos*

Volume 19, Issue 1, 2022

Published on: 03 June, 2022

Page: [3 - 6] Pages: 4

DOI: 10.2174/1875692119666220603154831

« Previous Next »
[1]
Nichols E, Steinmetz JD, Vollset SE, et al. GBD 2019 dementia forecasting collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7(2): e105-25.
[http://dx.doi.org/10.1016/S2468-2667(21)00249-8]
[2]
Cantarero-Prieto D, Leon PL, Blazquez-Fernandez C, Juan PS, Cobo CS. The economic cost of dementia: A systematic review. Dementia 2020; 19(8): 2637-57.
[http://dx.doi.org/10.1177/1471301219837776] [PMID: 30909718]
[3]
Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos P, Teijido Ó. Pharmacogenetics of vascular risk factors in Alzheimer’s disease. J Pers Med 2018; 8(1): 3.
[http://dx.doi.org/10.3390/jpm8010003] [PMID: 29301387]
[4]
Cacabelos R. What have we learnt from past failures in Alzheimer’s disease drug discovery? Expert Opin Drug Discov 2022; 17(4): 309-23.
[http://dx.doi.org/10.1080/17460441.2022.2033724] [PMID: 35129021]
[5]
Cacabelos R. Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov 2018; 13(6): 523-38.
[http://dx.doi.org/10.1080/17460441.2018.1457645] [PMID: 29607687]
[6]
Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol 2019; 12(5): 407-42.
[http://dx.doi.org/10.1080/17512433.2019.1597706] [PMID: 30916581]
[7]
Cacabelos R. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Metab Toxicol 2020; 16(8): 673-701.
[http://dx.doi.org/10.1080/17425255.2020.1779700] [PMID: 32520597]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy